Tarun katheriya | Stem Cell Research | Research Excellence Award

Published on by Cell Biologist

Dr. Tarun katheriya | Stem Cell Research | Research Excellence Award

IIT BHU Varanasi | India

Tarun Katheriya is a physicist with extensive expertise in the synthesis, characterization, and analysis of advanced functional materials, particularly negative-permittivity ceramics, perovskites, and multifunctional composites for electromagnetic interference (EMI) shielding and wearable electronics. His Ph.D. research focused on developing epsilon-negative materials, including layered perovskites and glass-ceramics, with tunable dielectric and conductive properties. He has synthesized a variety of electro-ceramics and glass-ceramics, exploring their dielectric behavior through classical and modified Drude models, and demonstrated their EMI shielding effectiveness. Notably, his work includes investigating coil-less inductive properties in conducting ceramics and studying the electrochemical performance of these materials. Katheriya has contributed to understanding the correlation between conductivity and permittivity in doped perovskites, as well as high-temperature dielectric properties in layered oxides. His research integrates experimental synthesis with theoretical modeling, advanced characterization techniques such as XRD, SEM, impedance analysis, and vector network analysis, and simulation tools including FullProf, Zview, and Gaussian. His published work highlights innovations in metal-free nanocomposites, negative-permittivity behavior, and multifunctional EMI shielding, positioning him at the forefront of materials development for next-generation electronic applications.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications: 

  1. Katheriya, T., Pandey, S., & Upadhyay, S. (2025). New frontiers in ceramic composites: Tunable electromagnetic interference shielding by realizing negative permittivity in SnO₂/LaNiO₃ nanocomposites. Journal of Materials Chemistry C.

  2. Katheriya, T., Nirala, G., & Upadhyay, S. (2025). Study of negative permittivity in nanosized LaNiO₃ for electromagnetic interference shielding: A modified Drude model approach. ACS Applied Electronic Materials.

  3. Katheriya, T., Nirala, G., & Upadhyay, S. (2024). Establishing the correlation of negative permittivity and AC conductivity of La₂₋ₓSrₓNiO₄ (x = 0, 0.1, 0.3, 1.0) for microwave shielding applications. Journal of Materials Chemistry C, 12(23), 8473–8484.

  4. Katheriya, T., & Upadhyay, S. (2023). High-temperature study of dielectric and electrical conduction behavior of La₂NiO₄. Physica Scripta, 98(10), 105969.

  5. Verma, H., Mittal, A., Kumar, P., Katheriya, T., Bhattacharya, B., & Upadhyay, S. (2025). Enhanced supercapacitor performance of rGO-modified LaFeO₃ perovskite: Experimental and DFT insights. Materials Chemistry and Physics, 131771.

  1. Nirala, G., Katheriya, T., Yadav, D., Verma, H., & Upadhyay, S. (2023). The evolution of coil-less inductive behavior in La-doped Sr₂MnO₄. Emergent Materials, 6(6), 1951–1962. https://doi.org/[DOI if available]Nirala, G., Yadav, D., Katheriya, T., & Upadhyay, S. (2022). Temperature-dependent negative permittivity in solid solutions Sr₂Mn₁₋ₓSnₓO₄ (x = 0, 0.3, 0.5). Journal of the European Ceramic Society, 42(2), 453–461.

  2. Nirala, G., Katheriya, T., Yadav, D., Pandey, S., & Upadhyay, S. (2022). Effect of Nb doping on epsilon negative behaviour of Sr₂MnO₄. Journal of Materials Science, 57(33), 15862–15875.

  3. Mishra, R. K., Avinashi, S. K., Kumari, S., Nain, R., Katheriya, T., Dwivedi, R. K., … Gautam, C. (2024). Synergistic doping effect of La₂O₃ on BaO–TiO₂–SiO₂ glass-ceramics: Evolution of physical, structural, morphological, and dielectric behaviour for electronics applications. Journal of Alloys and Compounds, 990, 174354.

Zhaowei Feng | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Zhaowei Feng | Stem Cell Research | Best Researcher Award

Dr. Zhaowei Feng, The Second Affiliated Hospital of Xuzhou Medical University, China

Zhaowei Feng is a dedicated biomedical researcher specializing in neurobiology and pharmacology, currently serving as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. With a solid academic foundation and a passion for neuroscience, Feng has made significant contributions to understanding mechanisms of neuroprotection and demyelination. His research spans neurodegenerative disease models such as multiple sclerosis and neonatal hypoxia-ischemia, utilizing molecular and cellular biology tools. Known for his collaborative nature and scientific rigor, Feng has co-authored multiple peer-reviewed articles in prestigious journals and has played pivotal roles in various national and municipal-level research projects. He is particularly recognized for co-first authorship in several studies, reflecting leadership in experimental design and data analysis. His growing influence in the field is further supported by ongoing funded projects and a research trajectory aimed at translational outcomes. Feng is committed to continuing impactful research that bridges bench science with clinical applications.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Strong Research Focus in Neurobiology 🧠
    Zhaowei Feng has a consistent and impactful research portfolio in neurobiology, particularly in myelination, ischemia-reperfusion injury, and glutamate signaling. His work is highly relevant in addressing diseases like multiple sclerosis and neonatal hypoxia-ischemia encephalopathy.

  2. Publications in High-Impact Journals 📚
    He has co-authored several peer-reviewed journal articles in reputable journals such as Phytomedicine, Pharmacology, Oncology Reports, and Frontiers. His contributions as co-first author in multiple papers reflect significant involvement in study design and experimentation.

  3. Independent Researcher Role 🧪
    He currently serves as a Principal Investigator for a municipal-level research project funded by the Xuzhou Health Commission, demonstrating trust in his leadership and research direction.

  4. Multidisciplinary Expertise 🔬
    His research integrates pharmacology, molecular biology, and neuroscience, covering diverse mechanisms like PPARγ signaling, SUMOylation, and ferroptosis, which enhances translational potential.

  5. Rapid Academic Growth 🚀
    Transitioning quickly from a Master’s student (2019–2022) to Assistant Researcher and PI (since 2022) shows a fast-tracked academic trajectory.

⚠️ Areas for Improvement:

  1. Need for More First-Author and Corresponding-Author Papers ✍️
    While co-first authorship is commendable, a stronger emphasis on sole first or corresponding authorship in future publications would establish more scientific independence.

  2. Limited Recognition at National Level 🏅
    Most current funding and achievements are at the municipal level. Applying for national or international grants (e.g., NSFC, NIH) would elevate his research profile.

  3. Postdoctoral Training or Collaboration Abroad 🌍
    Gaining international experience or collaborating with global research centers could broaden perspectives and techniques, increasing citation impact and networking.

  4. More Diversified Research Outputs 📊
    Exploring patents, clinical trials, or translational research outcomes could further demonstrate innovation and application potential.

🎓 Education:

Zhaowei Feng began his academic journey in the biological sciences at Xuzhou Medical University, where he earned his Bachelor’s degree between 2014 and 2018. He further pursued a Master’s degree in Neurobiology at the same institution from September 2019 to July 2022. His graduate studies were marked by an intensive focus on neurodegenerative mechanisms, including demyelination and neuroinflammation, with particular attention to cuprizone-induced and ischemia-reperfusion mouse models. His research also explored glutamate transport regulation, the PPARγ pathway, and oligodendrocyte differentiation. His educational foundation not only provided him with technical proficiency in experimental neuroscience but also cultivated a strong understanding of translational biomedical research. Through rigorous coursework, laboratory experience, and thesis writing, Feng developed a robust academic profile that seamlessly transitioned into his research career. His educational journey reflects consistent dedication and a clear trajectory towards clinical and experimental neurobiology.

🧪 Experience:

Since September 2022, Zhaowei Feng has been working as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. His role involves leading preclinical studies, managing collaborative projects, and mentoring junior researchers. Feng has also served as Principal Investigator on a municipal-level research grant focusing on blood-brain barrier damage post-transplantation. He actively participates in multiple interdisciplinary studies involving neurodevelopment, myelination, and pharmacological interventions. Prior to his current role, his Master’s research provided hands-on experience with animal models, molecular techniques, and data analysis in neurobiology. Feng has authored or co-authored numerous research papers, some as co-first author, contributing significantly to study design and execution. He is also involved in translational research projects that aim to bridge laboratory findings with clinical therapies. His work ethic, attention to detail, and innovative approach make him a valuable contributor to the field of neurobiological research.

🏅 Awards and Honors:

Zhaowei Feng has been recognized for his scientific contributions through both academic and research-oriented accolades. Notably, he is the recipient of a research grant from the Xuzhou Municipal Health Commission (Project No. XWKYHT20230029), focusing on cerebral ischemia-reperfusion and blood-brain barrier injury. Though early in his professional career, his selection as Principal Investigator on this project signifies trust in his leadership and expertise. Several of his publications in high-impact journals list him as co-first author—an honor that highlights his equal contribution in rigorous experimental work. While he has yet to receive national awards such as from the Natural Science Foundation, his steady academic output and funded research projects mark a strong trajectory. His growing publication record and role in significant studies position him as a rising talent in the biomedical field. Future honors are likely as his research continues to address key questions in neuroscience and pharmacology.

🔬 Research Focus:

Zhaowei Feng’s research centers on neuroprotection, demyelination, and neuroinflammation, with a particular focus on the mechanisms underlying multiple sclerosis, ischemic brain injury, and neonatal encephalopathy. His studies often employ animal models such as cuprizone-induced demyelination and hypoxia-ischemia to explore therapeutic targets. Feng is particularly interested in the regulation of oligodendrocyte differentiation and the role of glutamate transporters, signaling molecules like PPARγ, and pathways involving Wnt/β-catenin and SUMOylation. Additionally, he has investigated compounds such as diosgenin and alpha-asaronol for their neuroprotective and remyelination-promoting effects. His work also extends into cancer biology, with studies on ferroptosis and protein regulation in squamous cell carcinoma. By integrating molecular biology, pharmacology, and neurodevelopmental research, Feng aims to contribute to the discovery of new treatments for central nervous system disorders. His current and future research is geared toward translational medicine that bridges laboratory science with clinical applications.

📚 Publication Top Notes:

  1. 🧠 Alpha-Asaronol Alleviates Dysmyelination by Enhancing Glutamate Transport via PPARγ-GLT-1 Signaling in Neonatal Hypoxia-Ischemia (Pharmacology, 2022)

  2. 🧬 C1q Inhibits Differentiation of Oligodendrocyte Progenitor Cells via Wnt/β-Catenin Signaling (Biomedicine & Pharmacotherapy, 2023)

  3. 🧪 Alpha-Asaronol Promoted OPC Differentiation and Improved Myelination as a PPARγ Activator (Frontiers, 2023)

  4. 🧫 Diosgenin Promoted OPC Differentiation by Blocking GLUR2/GAPDH Interaction in Pilocarpine-Induced Epilepsy Rats (Phytomedicine, 2025)

  5. 🧬 Netrin-4 Mediates Piezo1 Inactivation and YAP Signaling Alleviation in Cerebral Ischemia-Reperfusion (Oncology Reports)

  6. 🔬 SENP1 Inhibits Ferroptosis and Promotes Head and Neck Squamous Cell Carcinoma by Regulating ACSL4 Protein (Molecular Oncology, 2023)

  7. 🧪 SUMO1-Mediated Stabilization Enhances Protein Function in Neuroinflammatory Models (Unspecified Journal)

  8. 🧠 Signaling Activation in a Cuprizone-Induced Mouse Model of Multiple Sclerosis (Unspecified Journal)

📌 Conclusion:

Zhaowei Feng is a highly promising early-career researcher with a clear scientific focus, a growing publication record, and demonstrated ability to lead independent research. His work addresses critical challenges in neurobiology and pharmacology, making a tangible impact in both experimental and translational medicine. With continued progression—especially toward national-level recognition and senior authorship—he has the potential to become a leader in his field.

Francesco Gaudio | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Francesco Gaudio | Stem Cell Research | Best Researcher Award

Prof. Francesco Gaudio, LUM UNIVERSITY, Italy

Prof. Francesco Gaudio is a highly accomplished hematologist with over 20 years of clinical and academic expertise, specializing in lymphoproliferative neoplasms and hematopoietic stem cell transplantation. Currently serving as Assistant Professor in Hematology at University LUM Giuseppe Degennaro and a practicing medical doctor at “F. Miulli” Hospital, he has previously held long-term roles at renowned Italian hospitals. With a prolific research record, he has authored over 50 publications in high-impact journals and contributed more than 100 abstracts to international conferences. He has conducted research in leading global institutions, including Memorial Sloan-Kettering and Imperial College. Alongside clinical innovation, he is a passionate educator and experienced healthcare manager. His focus on therapeutic advances and multidisciplinary care makes him a leader in hematology research and oncology care.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Extensive Clinical and Academic Experience
    Over 20 years of dedicated work in hematology, with expertise in lymphoproliferative disorders and hematopoietic stem cell transplantation.

  2. Robust Research Profile

    • More than 50 peer-reviewed publications in Impact Factor journals.

    • 100+ abstracts presented internationally.

    • Principal and co-investigator in multinational clinical studies.

  3. Global Exposure & Collaborations
    Research training and collaborations at globally recognized centers:

    • Memorial Sloan-Kettering (USA)

    • Imperial College (UK)

    • Lyon Sud (France)

    • VHIO Barcelona (Spain)

  4. Commitment to Academic Growth

    • Teaches Blood Diseases, Oncology, and Pathology.

    • Holds National Scientific Qualification for Associate Professor level.

  5. Leadership & Management Training

    • Managerial courses from SDA Bocconi, ISTUD Foundation, and CURSUS.

  6. Multidisciplinary Impact
    Engages in translational research that bridges hematology, oncology, and emerging areas like cannabinoid therapies and survivorship in cancer.

⚠️ Areas for Improvement:

  1. Leadership in High-Impact Authorship
    While his contribution as co-author is commendable, increasing first or senior authorship in landmark studies would strengthen his research leadership visibility.

  2. Grant Leadership and Funding Acknowledgment
    No mention of competitive grant acquisition or principal leadership in major funded research networks; pursuing this could enhance academic competitiveness.

  3. Public Engagement and Open Science
    Could further boost impact by increasing participation in open-access platforms, public talks, and wider media dissemination of research findings.

🎓 Education:

Prof. Gaudio holds a Degree in Medicine and Surgery from the University of Bari (1995–1996), where he explored clonogenic hematopoietic activity in lymphoma patients. He specialized in Hematology (2001–2002), focusing on stem cell mobilization challenges. He further expanded his scientific foundation with a Postgraduate Specialization in Chemico-Pharmaceutical Research from CARSO (1998). Recognized for academic excellence, he earned the National Scientific Qualification (ASN) for Associate Professor in Hematology, Oncology, and Rheumatology in 2020. His academic path is complemented by top-tier executive and managerial training, including healthcare leadership programs from SDA Bocconi, ISTUD Foundation, and CURSUS. Early education includes a Classical High School Diploma from Liceo Classico ‘Quinto Ennio’, Taranto. His diverse education underscores a balanced mastery of clinical medicine, research, and institutional leadership.

💼 Professional Experience:

Prof. Gaudio’s medical journey spans over two decades in hematology and oncology. Since April 2024, he serves as an Assistant Professor at University LUM Giuseppe Degennaro and practices medicine at “F. Miulli” Regional Hospital. Prior to this, he was a senior hematologist at Policlinico Consorziale, AOU Bari for nearly 19 years, providing expert care and engaging in impactful research. He also worked at Ospedali Riuniti in Foggia, honing his clinical foundations. His experience includes leadership in clinical trials, management of complex hematologic malignancies, and therapeutic protocol development. He is a sought-after speaker, educator, and research collaborator with exposure to international institutions including Sloan-Kettering (USA), Imperial College (UK), and VHIO (Spain). His long-standing service and global outreach reflect deep dedication to patient care, academic excellence, and translational medicine.

🔬 Research Focus:

Prof. Gaudio’s research focuses on lymphomas, leukemias, and hematopoietic stem cell transplantation, combining clinical acumen with molecular innovation. As Principal Investigator in numerous global trials, he has helped shape advanced therapeutic strategies and enhance survival in hematological malignancies. His work delves into mobilization of CD34+ stem cells, radiotherapy-induced toxicity, and biological markers of malignancy. Recent systematic reviews explore epithelial–mesenchymal transcription factors, BPDCN, and the neurological impact of cannabidiol. His interests also span survivorship in Hodgkin lymphoma patients, with emphasis on long-term toxicity and risk evaluation. His teaching integrates updated scientific evidence into medical curricula, training the next generation of hematologists. International collaborations and cross-border research highlight his commitment to innovation and best practices in oncology. Prof. Gaudio’s work not only advances hematology but also bridges clinical gaps through interdisciplinary solutions.

📚 Publications Top Notes:

📄 Exploring the Role of Epithelial–Mesenchymal Transcriptional Factors Involved in Hematological Malignancy and Solid Tumors: A Systematic Review 🔬🧬

📄 Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors: Evaluating Background Parenchymal Enhancement and Radiotherapy-Induced Toxicity 🎗️📊

📄 Plerixafor in association with R-DHAP and G-CSF to mobilize a large number of CD34+ cells in patients with relapsed-refractory diffuse large B-cell lymphomas 🩸💉

📄 The Evolving Role of Cannabidiol-Rich Cannabis in People with Autism Spectrum Disorder: A Systematic Review 🌿🧠

📄 Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview 🔎🧫

📝 Conclusion:

Prof. Francesco Gaudio is a highly qualified and deserving candidate for the Best Researcher Award. His two decades of contribution to hematology and oncology, combined with a prolific publication record, international collaboration, and dedication to clinical innovation, clearly demonstrate excellence in medical research. While opportunities exist for expanded authorship leadership and grant visibility, his current achievements are deeply impactful and relevant to modern hematologic science. His work bridges bench-to-bedside approaches and continues to benefit both the scientific community and patient outcomes.